Multiple SclerosisCAVS-MSNCT04495556
Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
An observational study of Multiple Sclerosis, run by The Cleveland Clinic at 11 sites in 2 countries.
Trial summary
The need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance Imaging (MRI) is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist. Up to 20% of people diagnosed with MS (1 in 5) are later found not to have the disease. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- MRI
- How many people
- 420 participants
- Where
- 11 sitesin 2 countries
- Study dates
- 11 Jun 2020to 30 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study will recruit a total 400 participants. The study will include 200 patients presenting with typical first syndromes and will enroll an additional 200 patients with atypical presentations and radiological suspicion of the disease. Participants will be recruited from the patient populations followed at eleven different sites including: Cleveland Clinic, Johns Hopkins University, University of California San Francisco, University of Texas Austin, University of Colorado Denver, University of Toronto (St. Michael's Hospital), University of Vermont, University of Pennsylvania, Cedars Sinai Medical Center, University of Southern California, and Yale University. Study investigators will confirm eligibility criteria, and participants will then be enrolled into the study.
Who may be able to join
- Inclusion criteria for participants with typical presentations will include:
- Age 18 to 65 inclusive
- Referral to a study academic site for a clinical suspicion of MS
- Onset with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
- Able to provide written informed consent to participate in the study
- For participants referred for clinical suspicion of multiple sclerosis who had workup prior to referral or who are taking disease-modifying therapies for MS, digital availability of diagnostic cranial MRI with gadolinium within 3 months of initial symptoms
Show all 14Show fewer
- Onset of typical neurological symptoms within 10 years of screening.
- Inclusion criteria for participants with atypical presentations will include:
- Age 18 to 65 inclusive
- Referral to a study academic site for a suspicion of MS
- Onset with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS
- Able to provide written informed consent to participate in the study
- For participants referred for clinical suspicion of multiple sclerosis who had workup prior to referral or who are taking disease-modifying therapies for MS, digital availability of diagnostic cranial MRI with gadolinium within 3 months of initial symptoms
- Onset of atypical neurological symptoms within 10 years of screening.
Who cannot join
- Exclusion criteria for both typical and atypical populations will include:
- Contraindication to MRI studies; metal or metal implants incompatible with MRI
- Inability to tolerate MRI due to claustrophobia or known excessive movement (e.g. tremor)
- Contraindication to use of gadolinium containing contrast agents (allergy or renal failure)
- Treatment with systemic corticosteroids in the 4 weeks preceding enrollment.
Trial locations and contacts
11 sites in 2 countries.
11 sites in 2 countries
United States10 sites
University of Colorado
Aurora, Colorado, 80045
The University of Texas at Austin
Austin, Texas, 78759
Johns Hopkins University
Baltimore, Maryland, 21218
University of Vermont
Burlington, Vermont, 05405
Cleveland Clinic Foundation
Cleveland, Ohio, 44195
Cedars-Sinai Medical Center
Los Angeles, California, 90048
University of Southern California
Los Angeles, California, 90089
Yale University
New Haven, Connecticut, 06520
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Washington University in St. Louis
St Louis, Missouri, 63130
Canada1 site
St. Michael's Hospital of Unity Health Toronto
Toronto, Ontario, M5B1W8
About this study
The need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance Imaging (MRI) is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist. Up to 20% of people diagnosed with MS (1 in 5) are later found not to have the disease. This is highly consequential, as more than two-thirds of misdiagnosed patients are unnecessarily exposed to risks from disease-modifying therapies, which in rare cases can be life-threatening.
Moreover, the current standard in MS diagnosis - the McDonald criteria, which combine clinical symptoms and MRI findings - were developed from studies in people with typical clinical presentations of MS. This reduces the specificity of these criteria, rendering them uninformative for the nearly half of MS patients who present to neurologists with atypical or nonclassical symptoms.
Read more
Timeliness of MS diagnosis is also key, as diagnostic delay is common in cases of relapsing-remitting MS and can carry severe and lifelong consequences.
The CentrAl Vein Sign in MS (CAVS-MS) study has been designed to assess whether Central Vein Sign (CVS) criteria can help address some of these unmet diagnostic needs. It will specifically explore the role of presentation type by enrolling a mixed population of patients with typical clinical presentations (n = 200) and those with atypical presentations, including suggestive MRI findings in the absence of neurologic symptoms (n = 200) across North America.
Read the detailed description
The CentrAl Vein Sign in MS (CAVS-MS) study seeks to answer whether the central vein sign (CVS) can be used as a sensitive and specific diagnostic marker for a diagnosis of MS. The study will investigate the CVS in a mixed population of participants with typical and atypical clinical presentations including radiological presentations without neurological symptoms.
The CVS is proposed as a diagnostic biomarker with improved sensitivity for a diagnosis of MS, while retaining diagnostic specificity - all in an-easy-to use diagnostic test that can be applied in patients with both typical and atypical disease presentation. There is extensive research demonstrating the ability of the CVS criteria to discriminate MS lesions from common mimickers, such as vascular disease and migraine. However, the CVS has mainly been applied in cross- sectional studies. In addition, the majority of these studies have focused analysis primarily on patients presenting with typical clinical events of demyelination (i.e. a classic Clinically Isolated Syndrome (CIS)). This study will evaluate CVS criteria prospectively in individuals with typical and atypical MS presentations. Aim 1 will examine sensitivity and specificity of CVS criteria in conjunction with, and separate from, the McDonald Criteria. Aim 2 will examine CVS in a population where McDonald criteria explicitly cannot be applied. Because the likelihood of MS is lower in this group, the focus will be on specificity, which is where the unmet need exists.
Although current MS diagnostic criteria are sensitive in most typical cases, the use of the CVS may hasten diagnosis in patients with low lesion numbers and those without dissemination in time. In the past, studies that informed revision of the diagnostic criteria used "clinically definite MS" (defined as two separate clinical events) as the definitive determination of a diagnosis. In the current treatment era, however, clinically definite MS is less relevant, since most patients will be diagnosed after a first clinical event (relapse) and will go on to start treatment prior to even having a second relapse. For this reason, the 2017 McDonald Criteria is being used as the "gold standard" for the proposed study.
Importantly, in the current study the CVS will be applied in a population where the McDonald Criteria are not applicable (atypical presentations) and where currently a significant unmet clinical need exists. Because the studies that informed the diagnostic criteria did not include patients presenting with atypical syndromes, such patients are not covered in the McDonald Criteria path, but are frequently given a diagnosis of MS on the basis of MRI findings. To address this limitation, the presence of CVS as a predictor of development of future clinical events will be examined, within a 24- month period, that would satisfy the 2017 McDonald Criteria. Thus, the results of this study will have a significant impact on both improving sensitivity in those presenting with typical presentations and providing a specific test for MS in those with atypical presentations, thereby avoiding unnecessary costs associated with misdiagnosis. The investigators will leverage the North American Imaging in Multiple Sclerosis Cooperative (NAIMS) to conduct a multicenter study, based on an initial cross-sectional pilot study using the CVS criteria as a diagnostic biomarker for MS.
Patients will be enrolled when presenting to an MS center for diagnostic referral, and they will undergo follow-up at prespecified intervals for 24 months. Brain MRI will be performed at baseline and 24 months, with scans scored on the basis of CVS criteria. T2-weighted fluid-attenuated inversion recovery (FLAIR) imaging will be combined with T2*-weighted segmented echo-planar imaging to enable simultaneous identification of white matter lesions and venous structures.
The primary objective is to determine whether use of CVS criteria allows for an earlier accurate diagnosis of MS in patients who do not meet the McDonald criteria at baseline. The aim is to show that the CVS is a simple and reliable diagnostic biomarker that will show an increase in sensitivity while preserving specificity.
Secondary objectives include the following:
- Determining concordance of CVS criteria and the McDonald criteria among patients meeting McDonald criteria at baseline.
- Determining whether use of CVS criteria improves diagnostic specificity for MS in people presenting with atypical symptoms.
- Determining whether the CVS predicts development of clinical MS in individuals with suggestive radiologic findings but no symptoms.
The researchers will also begin exploratory studies of optimal methods for integrating CVS findings into MS diagnostic criteria, along with any resulting healthcare-related cost savings. These initial exploratory analyses will be important to how readily positive findings about the utility of CVS criteria can impact clinical practice. The ultimate goal is to have the CVS incorporated into the MS diagnostic criteria.
- Conditions
- Multiple Sclerosis
- Being tested
- MRI
- Keywords
- Multiple Sclerosis, MS, MRI, Central Vein Sign, CVS, Diagnostic Biomarker, Autoimmune disease
- Medical subject headings
- Multiple Sclerosis, Autoimmune Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MRIDiagnostic test
The study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS.
| Study group | Role | What they receive |
|---|---|---|
| Typical | Patients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator. Receives: Diagnostic Test: MRI | |
| Atypical | Patients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS. Receives: Diagnostic Test: MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
MRI Outcomes
MRI will be done to assess sensitivity and specificity of the CVS for multiple sclerosis.
MRI will be done at baseline or start of the study and at month 24, end of study. Central veins will be counted and lesions will be considered CVS+ using specified criteria. CVS will be determined using Select6, Select3*, and automated lesion analysis with inclusion and exclusion of periventricular lesions.
Measured: Change assessed over 24 months. First scan at baseline (first study visit) and the second scan at 24 months or the last study visit.
Secondary outcomes (9)
Clinical Outcomes - McDonald Criteria 2017
Determination of a diagnosis of MS using the McDonald Criteria 2017 will be conducted by a central adjudication committee. McDonald diagnostic criteria for MS are clinical, radiographic, and laboratory criteria used in the diagnosis of multiple sclerosis. Members of the adjudication committee will separately review the clinical data, laboratory testing, and study MRIs of each participant at baseline, 12 months, and 24 months.
Measured: McDonald criteria will be reviewed at baseline, month 12 and month 24 visits.
Clinical Outcomes - Relapses
Relapses will be assessed at every study visit after baseline to look for disease progression and disability. Proportion of people who do not have clinical relapses of MS at 24 months, will help us determine if CVS yields specificity for MS among individuals with atypical presentation.
Measured: Relapses will be assessed at month 6, month 12, month 18 and month 24.
Clinical Outcomes - Lab results - Cerebrospinal Fluid Testing
Lab results will be collected at every study visit whenever available. May include recording of: cerebrospinal fluid testing (CSF).
Measured: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Lab results - Neuromyelitis Optica Antibodies (NMO-IgG)
Lab results will be collected at every study visit whenever available. May include recording of: neuromyelitis optica antibodies (NMO-IgG).
Measured: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Lab results - Myelin oligodendrocyte glycoprotein (MOG) testing.
Lab results will be collected at every study visit whenever available. May include recording of: myelin oligodendrocyte glycoprotein (MOG) testing.
Measured: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Patient reported Outcomes - Change in Neuro-QoL (Quality of Life in Neurological disorders) using Neuro-QoL short forms to assess Physical Domains, from baseline to month 24.
The Neuro-QoL (short forms) instrument will be used to measure quality of life as related to neurological disease.
11 subscales, each is scored separately, there is no composite score.
Physical Domains include:
Upper Extremity Function (Fine Motor, ADL), Lower Extremity Function (Mobility), Fatigue, and Sleep Disturbance.
Measured: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Change in Neuro-QoL using Neuro-QoL short forms to assess Mental Domains, from baseline to month 24
The Neuro-QoL (short forms) instrument will be used to measure quality of life as related to neurological disease.
11 subscales, each is scored separately, there is no composite score.
Mental Domains include:
Cognition Function, Stigma, Anxiety, Depression and Positive Affect and Well-being.
Measured: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Change in Neuro-QoL using Neuro-QoL short forms to assess Social Domains, from baseline to month 24
The Neuro-QoL (short forms) instrument will be used to measure quality of life as related to neurological disease.
11 subscales, each is scored separately, there is no composite score.
Social Domains include:
Ability to Participate in Social Roles and Activities, and Satisfaction with Social Roles and Activities.
Measured: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Patient reported Outcomes - PDDS (patient determined disease steps)
The PDDS is a patient reported outcome that captures overall MS disability. It will be collected and baseline, month 6, month 12, month 18, and month 24. PDDS scores will be recorded and sustained worsening will be considered for worsening of 1 point or greater confirmed at 3 months.
Measured: PDDS will be assessed at all the 5 study visits - baseline, month 6, 12, 18 and 24.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2020
- Study start11 Jun 2020
- Primary completion30 Jun 2026
- Study completion30 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by The Cleveland ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 420 participants (actual)
Sponsor and investigators
- Lead sponsor
- The Cleveland Clinic
- Sponsor type
- University, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS), University of Pennsylvania, Cedars-Sinai Medical Center, National Institutes of Health (NIH)
- Responsible party
- Principal investigator, Daniel Ontaneda, MD, The Cleveland Clinic
- Investigators
- Daniel Ontaneda, MD, PhD, Principal investigator, The Cleveland ClinicNancy Sicotte, MD, Principal investigator, Cedars-Sinai Medical CenterPascal Sati, PhD, Principal investigator, Cedars-Sinai Medical Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04495556
- Sponsor's protocol ID
- 20-063
- Other IDs
- 1U01NS116776-01
- Acronym
- CAVS-MS
- Status last verified
- Oct 2026
- First submitted
- 23 Jul 2020
- Last updated
- 16 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Central Vein Sign: a Diagnostic Biomarker in Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT04495556
- Acronym / sponsor ID
- CAVS-MS / 20-063
- Conditions
- Multiple Sclerosis
- Keywords
- Multiple Sclerosis, MS, MRI, Central Vein Sign, CVS, Diagnostic Biomarker, Autoimmune disease
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 420 participants (actual)
- Lead sponsor
- The Cleveland ClinicUniversity, hospital or other
- Collaborators
- National Institute of Neurological Disorders and Stroke (NINDS), University of Pennsylvania, Cedars-Sinai Medical Center, National Institutes of Health (NIH)
- Study start
- 11 Jun 2020 (actual)
- Primary completion
- 30 Jun 2026 (actual)
- Study completion
- 30 Jun 2026 (actual)
- First posted
- 3 Aug 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance Imaging (MRI) is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist. Up to 20% of people diagnosed with MS (1 in 5) are later found not to have the disease. This is highly consequential, as more than two-thirds of misdiagnosed patients are unnecessarily exposed to risks from disease-modifying therapies, which in rare cases can be life-threatening.
Moreover, the current standard in MS diagnosis - the McDonald criteria, which combine clinical symptoms and MRI findings - were developed from studies in people with typical clinical presentations of MS. This reduces the specificity of these criteria, rendering them uninformative for the nearly half of MS patients who present to neurologists with atypical or nonclassical symptoms.
Timeliness of MS diagnosis is also key, as diagnostic delay is common in cases of relapsing-remitting MS and can carry severe and lifelong consequences.
The CentrAl Vein Sign in MS (CAVS-MS) study has been designed to assess whether Central Vein Sign (CVS) criteria can help address some of these unmet diagnostic needs. It will specifically explore the role of presentation type by enrolling a mixed population of patients with typical clinical presentations (n = 200) and those with atypical presentations, including suggestive MRI findings in the absence of neurologic symptoms (n = 200) across North America.
Detailed description
The CentrAl Vein Sign in MS (CAVS-MS) study seeks to answer whether the central vein sign (CVS) can be used as a sensitive and specific diagnostic marker for a diagnosis of MS. The study will investigate the CVS in a mixed population of participants with typical and atypical clinical presentations including radiological presentations without neurological symptoms.
The CVS is proposed as a diagnostic biomarker with improved sensitivity for a diagnosis of MS, while retaining diagnostic specificity - all in an-easy-to use diagnostic test that can be applied in patients with both typical and atypical disease presentation. There is extensive research demonstrating the ability of the CVS criteria to discriminate MS lesions from common mimickers, such as vascular disease and migraine. However, the CVS has mainly been applied in cross- sectional studies. In addition, the majority of these studies have focused analysis primarily on patients presenting with typical clinical events of demyelination (i.e. a classic Clinically Isolated Syndrome (CIS)). This study will evaluate CVS criteria prospectively in individuals with typical and atypical MS presentations. Aim 1 will examine sensitivity and specificity of CVS criteria in conjunction with, and separate from, the McDonald Criteria. Aim 2 will examine CVS in a population where McDonald criteria explicitly cannot be applied. Because the likelihood of MS is lower in this group, the focus will be on specificity, which is where the unmet need exists.
Although current MS diagnostic criteria are sensitive in most typical cases, the use of the CVS may hasten diagnosis in patients with low lesion numbers and those without dissemination in time. In the past, studies that informed revision of the diagnostic criteria used "clinically definite MS" (defined as two separate clinical events) as the definitive determination of a diagnosis. In the current treatment era, however, clinically definite MS is less relevant, since most patients will be diagnosed after a first clinical event (relapse) and will go on to start treatment prior to even having a second relapse. For this reason, the 2017 McDonald Criteria is being used as the "gold standard" for the proposed study.
Importantly, in the current study the CVS will be applied in a population where the McDonald Criteria are not applicable (atypical presentations) and where currently a significant unmet clinical need exists. Because the studies that informed the diagnostic criteria did not include patients presenting with atypical syndromes, such patients are not covered in the McDonald Criteria path, but are frequently given a diagnosis of MS on the basis of MRI findings. To address this limitation, the presence of CVS as a predictor of development of future clinical events will be examined, within a 24- month period, that would satisfy the 2017 McDonald Criteria. Thus, the results of this study will have a significant impact on both improving sensitivity in those presenting with typical presentations and providing a specific test for MS in those with atypical presentations, thereby avoiding unnecessary costs associated with misdiagnosis. The investigators will leverage the North American Imaging in Multiple Sclerosis Cooperative (NAIMS) to conduct a multicenter study, based on an initial cross-sectional pilot study using the CVS criteria as a diagnostic biomarker for MS.
Patients will be enrolled when presenting to an MS center for diagnostic referral, and they will undergo follow-up at prespecified intervals for 24 months. Brain MRI will be performed at baseline and 24 months, with scans scored on the basis of CVS criteria. T2-weighted fluid-attenuated inversion recovery (FLAIR) imaging will be combined with T2*-weighted segmented echo-planar imaging to enable simultaneous identification of white matter lesions and venous structures.
The primary objective is to determine whether use of CVS criteria allows for an earlier accurate diagnosis of MS in patients who do not meet the McDonald criteria at baseline. The aim is to show that the CVS is a simple and reliable diagnostic biomarker that will show an increase in sensitivity while preserving specificity.
Secondary objectives include the following:
- Determining concordance of CVS criteria and the McDonald criteria among patients meeting McDonald criteria at baseline.
- Determining whether use of CVS criteria improves diagnostic specificity for MS in people presenting with atypical symptoms.
- Determining whether the CVS predicts development of clinical MS in individuals with suggestive radiologic findings but no symptoms.
The researchers will also begin exploratory studies of optimal methods for integrating CVS findings into MS diagnostic criteria, along with any resulting healthcare-related cost savings. These initial exploratory analyses will be important to how readily positive findings about the utility of CVS criteria can impact clinical practice. The ultimate goal is to have the CVS incorporated into the MS diagnostic criteria.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Typical | – | Diagnostic Test: MRIPatients with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS (central nervous system) pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator. |
| Atypical | – | Diagnostic Test: MRIPatients with atypical onset including: bilateral optic neuritis or unilateral optic neuritis with a poor visual recovery, complete gaze palsy or fluctuating ophthalmoparesis, intractable nausea, vomiting, or hiccups, complete transverse myelopathy with bilateral motor and sensory involvement, encephalopathy, subacute cognitive decline, headache or meningismus, isolated fatigue or asthenia, constitutional symptoms, other clinical presentations considered atypical by the site investigator (examples include: vague or patchy sensory symptoms, pain, short lasting bilateral blurred vision, etc.), or absence of clinical symptoms with MRI features suggestive of MS. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study will recruit a total 400 participants. The study will include 200 patients presenting with typical first syndromes and will enroll an additional 200 patients with atypical presentations and radiological suspicion of the disease. Participants will be recruited from the patient populations followed at eleven different sites including: Cleveland Clinic, Johns Hopkins University, University of California San Francisco, University of Texas Austin, University of Colorado Denver, University of Toronto (St. Michael's Hospital), University of Vermont, University of Pennsylvania, Cedars Sinai Medical Center, University of Southern California, and Yale University. Study investigators will confirm eligibility criteria, and participants will then be enrolled into the study.
Key inclusion criteria (14 listed)
- Age 18 to 65 inclusive
- Referral to a study academic site for a clinical suspicion of MS
- Onset with typical symptom onset including: acute unilateral optic neuritis, double vision due to an internuclear ophthalmoplegia or sixth nerve palsy, facial sensory loss or trigeminal neuralgia in a young adult (<40 years of age), cerebellar ataxia and nystagmus, partial myelopathy, sensory symptoms in a CNS pattern, Lhermitte's symptom, asymmetric limb weakness, urge incontinence or erectile dysfunction, or other neurological presentation considered to be typical by the site investigator.
- Able to provide written informed consent to participate in the study
- For participants referred for clinical suspicion of multiple sclerosis who had workup prior to referral or who are taking disease-modifying therapies for MS, digital availability of diagnostic cranial MRI with gadolinium within 3 months of initial symptoms
Key exclusion criteria (5 listed)
- Contraindication to MRI studies; metal or metal implants incompatible with MRI
- Inability to tolerate MRI due to claustrophobia or known excessive movement (e.g. tremor)
- Contraindication to use of gadolinium containing contrast agents (allergy or renal failure)
- Treatment with systemic corticosteroids in the 4 weeks preceding enrollment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MRIThe study will include MRI at baseline (first study visit) and month 24 (final study visit). MRI at month 24 (end of study) will be used to determine McDonald Criteria and final review of CVS. | Diagnostic test | Atypical, Typical |
Primary outcome
MRI Outcomes
Time frame: Change assessed over 24 months. First scan at baseline (first study visit) and the second scan at 24 months or the last study visit.
MRI will be done to assess sensitivity and specificity of the CVS for multiple sclerosis. MRI will be done at baseline or start of the study and at month 24, end of study. Central veins will be counted and lesions will be considered CVS+ using specified criteria. CVS will be determined using Select6, Select3*, and automated lesion analysis with inclusion and exclusion of periventricular lesions.
9 secondary outcomes
Clinical Outcomes - McDonald Criteria 2017
Time frame: McDonald criteria will be reviewed at baseline, month 12 and month 24 visits.
Clinical Outcomes - Relapses
Time frame: Relapses will be assessed at month 6, month 12, month 18 and month 24.
Clinical Outcomes - Lab results - Cerebrospinal Fluid Testing
Time frame: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Lab results - Neuromyelitis Optica Antibodies (NMO-IgG)
Time frame: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Lab results - Myelin oligodendrocyte glycoprotein (MOG) testing.
Time frame: Lab results will be collected at baseline, month 6, month 12, month 18 and month 24.
Patient reported Outcomes - Change in Neuro-QoL (Quality of Life in Neurological disorders) using Neuro-QoL short forms to assess Physical Domains, from baseline to month 24.
Time frame: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Change in Neuro-QoL using Neuro-QoL short forms to assess Mental Domains, from baseline to month 24
Time frame: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Change in Neuro-QoL using Neuro-QoL short forms to assess Social Domains, from baseline to month 24
Time frame: Assessed over 24 months. Neuro-QoL at baseline, month 12 and month 24 study visits.
Patient reported Outcomes - PDDS (patient determined disease steps)
Time frame: PDDS will be assessed at all the 5 study visits - baseline, month 6, 12, 18 and 24.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Multiple Sclerosis
RecruitingPhase 4
Individualised Cryoneurolysis to Treat Pain in the Context of Spasticity in the Upper and Lower Extremities
Centreal Neurological Condition, Acquired Brain Injury (Including Stroke)
Active, not recruiting
Myrosinase Bioactivated Gglucoraphanin for the Treatment of Neurodegenerative Diseases (GRA-MYR-ND)
PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Not yet recruitingPhase 1
A Study of Subcutaneously Administered RO7845860 in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Recruiting
Virtual Reality Versus Mental Practice On Balance And Gait In Patients With Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Ontaneda, MD, PhD principal investigator
The Cleveland Clinic
Nancy Sicotte, MD principal investigator
Cedars-Sinai Medical Center
Pascal Sati, PhD principal investigator
Cedars-Sinai Medical Center
11 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Multiple Sclerosis, run by The Cleveland Clinic at 11 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 16 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 11 sites in United States, Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MRI Outcomes (time frame: Change assessed over 24 months. First scan at baseline (first study visit) and the second scan at 24 months or the last study visit.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Oct 2026; AzTrials last refreshed its copy on 6 Nov 2026.